Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Abingdon Health Plc (ABDXF)
York, GB
Abingdon Health Plc is a global enterprise dedicated to the innovation, production, and worldwide distribution of diagnostic technologies. Their diverse product portfolio includes rapid self-diagnostic tools like the AbC-19 Rapid Test for detecting COVID-19 IgG antibodies and the 2019-nCoV Antigen Test for identifying SARS-CoV-2 antigens. They also offer a range of nucleic acid lateral flow immunoassays, including the PCRD and PCRD FLEX systems, which provide quick readouts following isothermal amplification. The 'Abingdon Simply Test' line further expands their selection of consumer-friendly self-tests. Beyond physical tests, Abingdon Health provides AppDx, an innovative, customizable image-capturing technology that essentially transforms any smartphone into a self-contained lateral flow reader. The company also extends its expertise through a variety of services, including contract manufacturing, bespoke nucleic acid lateral flow test customization, and comprehensive lateral flow development and production. Additionally, they offer strategic consultancy to businesses operating within the healthcare technology sector. Notably, Abingdon Health Plc maintains a significant collaboration and co-marketing agreement with Abcam plc. Founded in 2008, the company's operations are centrally managed from its headquarters in York, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +23.81% | +23.81% | +63.18% | +183.00% | +183.00% | +183.00% | +183.00% | +183.00% | +183.00% | +183.00% | +183.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Diagnostics & Research: +7.9%+37.4% ★ Q4'25: +251.6% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%-121.4% Q4'25: -200.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-43.8% Q4'25: -30.9% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-40.4% Q4'25: -67.4% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-77.3% Q4'25: -322.5% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+22.5% Q4'25: +29.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.37× Q4'25: -0.09× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 2 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
6.14M
est: 6.09M (+0.7%)
|
8.43M
est: 8.61M (-2.0%)
|
11.93M
11.91M – 11.95M
+38.7% YoY
|
14.87M
14.82M – 14.91M
+24.6% YoY
|
16.24M
16.21M – 16.26M
+9.2% YoY
|
| EBITDA |
-916.0K
est: -3.26M (+71.9%)
|
-2.80M
est: -4.61M (+39.2%)
|
-6.39M
-6.40M – -6.38M
-38.7% YoY
|
-7.96M
-7.98M – -7.94M
-24.6% YoY
|
-8.69M
-8.71M – -8.68M
-9.2% YoY
|
| EBIT |
-1.34M
est: -4.39M (+69.4%)
|
-3.41M
est: -6.19M (+45.0%)
|
-8.59M
-8.60M – -8.58M
-38.7% YoY
|
-10.70M
-10.73M – -10.67M
-24.6% YoY
|
-11.69M
-11.71M – -11.67M
-9.2% YoY
|
| Net Income |
-1.27M
|
-3.42M
est: -4.11M (+16.9%)
|
-876.1K
-878.0K – -874.2K
+78.7% YoY
|
547.6K
546.4K – 548.7K
+162.5% YoY
|
1.10M
1.09M – 1.10M
+100.0% YoY
|
| SGA |
5.07M
est: 7.46M (-32.1%)
|
7.71M
est: 10.54M (-26.8%)
|
14.62M
14.59M – 14.64M
+38.7% YoY
|
18.21M
18.16M – 18.26M
+24.6% YoY
|
19.89M
19.86M – 19.92M
+9.2% YoY
|
| EPS |
0.00
|
-0.01
est: -0.01 (+15.5%)
|
0.00
0.00 – 0.00
+78.7% YoY
|
0.00
0.00 – 0.00
+162.5% YoY
|
0.00
0.00 – 0.00
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher William Hand | Executive Chairman | 307.2K | — |
| Chris Henry Francis Yates | President of & Director Abingdon Health USA Inc. | 291.1K | male |
| Thomas Edward Hayes | Secretary, Chief Financial Officer & Director | 92.6K | male |
| Laura Towse | Controller | — | — |
| Mark Jones | Chief Operating Officer | — | male |
| Nina Garrett | Chief Technical Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABDXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
